
MNMD Stock Forecast & Price Target
MNMD Analyst Ratings
Bulls say
Mind Medicine Inc. is advancing its late-stage clinical pipeline with promising results for its lead product candidates, MM120 and MM402, which are targeting significant mental health disorders such as generalized anxiety disorder, clinical depressive disorder, and autism spectrum disorder. The Phase 2b data highlight that MM120 has achieved statistically significant improvements in both the Montgomery-Asberg Depression Rating Scale (MADRS) and the Hamilton Anxiety Rating Scale (HAM-A), indicating a compelling efficacy that surpasses current standard-of-care treatments. Furthermore, with both Phase 3 studies expected to read out in 2026, the company is positioned to capitalize on the increasing adoption and market potential of psychedelic therapies, offering a favorable outlook for its stock.
Bears say
Mind Medicine Inc. faces significant clinical and regulatory risks that could hinder the approval of its product candidates, specifically MM120 and MM402, impacting its financial viability and market potential. Additionally, the company is at a potential disadvantage if key patents are not secured or become contested, which may lead to insufficient protection for its assets and subsequently result in downward revisions of its valuation. Furthermore, conservative management assumptions regarding patient treatment frequency compared to earlier studies may indicate a lack of confidence in the effectiveness and market competitiveness of its therapies.
This aggregate rating is based on analysts' research of Mind Medicine MindMed and is not a guaranteed prediction by Public.com or investment advice.
MNMD Analyst Forecast & Price Prediction
Start investing in MNMD
Order type
Buy in
Order amount
Est. shares
0 shares